CERS
Price
$1.42
Change
+$0.06 (+4.41%)
Updated
Jun 27 closing price
Capitalization
342.62M
32 days until earnings call
XAIR
Price
$0.16
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
79.87M
39 days until earnings call
Interact to see
Advertisement

CERS vs XAIR

Header iconCERS vs XAIR Comparison
Open Charts CERS vs XAIRBanner chart's image
Cerus
Price$1.42
Change+$0.06 (+4.41%)
Volume$4.37M
Capitalization342.62M
Beyond Air
Price$0.16
Change-$0.00 (-0.00%)
Volume$2.89M
Capitalization79.87M
CERS vs XAIR Comparison Chart in %
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XAIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. XAIR commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Buy and XAIR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (CERS: $1.42 vs. XAIR: $0.16)
Brand notoriety: CERS and XAIR are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 367% vs. XAIR: 86%
Market capitalization -- CERS: $342.62M vs. XAIR: $79.87M
CERS [@Medical Specialties] is valued at $342.62M. XAIR’s [@Medical Specialties] market capitalization is $79.87M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileXAIR’s FA Score has 1 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • XAIR’s FA Score: 1 green, 4 red.
According to our system of comparison, CERS is a better buy in the long-term than XAIR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 5 TA indicator(s) are bullish while XAIR’s TA Score has 3 bullish TA indicator(s).

  • CERS’s TA Score: 5 bullish, 4 bearish.
  • XAIR’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CERS is a better buy in the short-term than XAIR.

Price Growth

CERS (@Medical Specialties) experienced а +5.97% price change this week, while XAIR (@Medical Specialties) price change was -30.97% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.08%. For the same industry, the average monthly price growth was +1.35%, and the average quarterly price growth was -0.23%.

Reported Earning Dates

CERS is expected to report earnings on Jul 31, 2025.

XAIR is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Medical Specialties (+1.08% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CERS($343M) has a higher market cap than XAIR($79.9M). CERS YTD gains are higher at: -7.792 vs. XAIR (-55.370). CERS has higher annual earnings (EBITDA): -26.34M vs. XAIR (-67.06M). CERS has more cash in the bank: 65.9M vs. XAIR (31.3M). XAIR has less debt than CERS: XAIR (16.9M) vs CERS (96M). CERS has higher revenues than XAIR: CERS (156M) vs XAIR (689K).
CERSXAIRCERS / XAIR
Capitalization343M79.9M429%
EBITDA-26.34M-67.06M39%
Gain YTD-7.792-55.37014%
P/E RatioN/AN/A-
Revenue156M689K22,642%
Total Cash65.9M31.3M211%
Total Debt96M16.9M568%
FUNDAMENTALS RATINGS
CERS vs XAIR: Fundamental Ratings
CERS
XAIR
OUTLOOK RATING
1..100
4089
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
31
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
5693
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XAIR's Valuation (31) in the null industry is in the same range as CERS (44) in the Medical Specialties industry. This means that XAIR’s stock grew similarly to CERS’s over the last 12 months.

XAIR's Profit vs Risk Rating (100) in the null industry is in the same range as CERS (100) in the Medical Specialties industry. This means that XAIR’s stock grew similarly to CERS’s over the last 12 months.

CERS's SMR Rating (96) in the Medical Specialties industry is in the same range as XAIR (100) in the null industry. This means that CERS’s stock grew similarly to XAIR’s over the last 12 months.

CERS's Price Growth Rating (56) in the Medical Specialties industry is somewhat better than the same rating for XAIR (93) in the null industry. This means that CERS’s stock grew somewhat faster than XAIR’s over the last 12 months.

CERS's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as XAIR (100) in the null industry. This means that CERS’s stock grew similarly to XAIR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSXAIR
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 13 days ago
81%
Declines
ODDS (%)
Bearish Trend 17 days ago
84%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XAIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LGGNY17.410.07
+0.40%
Legal & General Group Plc
CHGCY26.350.06
+0.23%
Chugai Pharmaceutical Co., Ltd.
LUNMF10.48-0.30
-2.80%
Lundin Mining Corp.
PTHRF0.34-0.01
-3.75%
Pantheon Resources Plc
VCUFF0.07N/A
-5.36%
Vizsla Copper Corp.

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
+4.41%
LAB - CERS
52%
Loosely correlated
-6.30%
NNOX - CERS
47%
Loosely correlated
-0.38%
SGHT - CERS
46%
Loosely correlated
+1.18%
UTMD - CERS
46%
Loosely correlated
+2.41%
BFLY - CERS
45%
Loosely correlated
-2.97%
More

XAIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XAIR has been loosely correlated with OPK. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if XAIR jumps, then OPK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XAIR
1D Price
Change %
XAIR100%
-2.02%
OPK - XAIR
35%
Loosely correlated
N/A
KIDS - XAIR
32%
Poorly correlated
-1.84%
SHWGY - XAIR
32%
Poorly correlated
N/A
CERS - XAIR
31%
Poorly correlated
+4.41%
IDXX - XAIR
31%
Poorly correlated
N/A
More